

State of Oklahoma SoonerCare



Loqtorzi[™] (Toripalimab-tpzi) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
☐ Physician billing (HCPCS code:) 🗌 Pharma	acy billing (NDC:)
Dose:Regimen:	gimen: Start Date (or date of next dose):	
Billing Provider Information		
Provider NPI:Provider Name:		
Provider Phone:	Provider Fax:_	
Prescriber Information		
Prescriber NPI:	Prescriber Name:_	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
 Nasopharyngeal Carcinoma (NPC) Other: Is disease metastatic or recurrent, locally advanced NPC? Yes No a. Will toripalimab-tpzi be used in the first-line setting? Yes No b. Will toripalimab-tpzi be used in combination with cisplatin and gemcitabine? Yes No 3. Is disease previously treated recurrent unresectable or metastatic NPC? Yes No a. Has disease progressed on or following a platinum-containing chemotherapy? Yes No b. Will toripalimab-tpzi be used as a single agent? Yes No C. Please provide member's weight (kg): Additional Information:		
3. Has member experienced adverse reaching specify adverse reaching specify adverse reaching specific	erse drug reactions related ctions: medically necessary and all in notes. Specific information will b	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 257 1/2/2024